CYP2D6 — Cytochrome P450 2D6

CYP2D6 — Cytochrome P450 2D6

Pathway Diagram

Overview

CYP2D6 — Cytochrome P450 2D6

Pathway Diagram

Overview

[CYP2D6](/genes/cyp2d6) (Cytochrome P450 Family 2 Subfamily D Member 6) encodes a crucial phase I drug-metabolizing enzyme that plays a pivotal role in the metabolism of approximately 25% of all clinically used drugs. Beyond its well-established role in pharmacogenomics, CYP2D6 has emerged as a significant player in neurodegenerative disease research, particularly through its capacity to metabolize endogenous neuroactive compounds, environmental neurotoxins, and neuroprotective substances.

The enzyme is remarkable for its extraordinary polymorphism, with over 100 known alleles that result in dramatically different enzyme activities across individuals. This genetic variability has profound implications for drug therapy in neurological and psychiatric conditions, and increasingly, for understanding individual susceptibility to neurodegenerative diseases.

<div class="infobox infobox-gene">
<h3>CYP2D6</h3>
<table>
<tr><th>Full Name</th><td>Cytochrome P450 Family 2 Subfamily D Member 6</td></tr>
<tr><th>Gene Symbol</th><td>CYP2D6</td></tr>
<tr><th>Chromosomal Location</th><td>22q13.2</td></tr>
<tr><th>NCBI Gene ID</th><td>[1565](https://www.ncbi.nlm.nih.gov/gene/1565)</td></tr>
<tr><th>OMIM</th><td>[171080](https://www.omim.org/entry/171080)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000100168</td></tr>
<tr><th>UniProt ID</th><td>[P10635](https://www.uniprot.org/uniprot/P10635)</td></tr>
<tr><th>Protein Length</th><td>497 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>[Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Drug Metabolism Disorders, Essential Tremor, Stroke</td></tr>
</table>
</div>

Molecular Function

Enzyme Activity

CYP2D6 is a heme-containing monooxygenase that catalyzes the oxidation of a diverse array of substrates through the addition of oxygen atoms and the removal of hydrogen[@cyp2d6_discovery][@cyp2d6_substrate_specificity]:

• Catalytic reaction type: Hydroxylation, O-dealkylation, N-dealkylation
• Cofactor requirement: NADPH-cytochrome P450 reductase
• Substrate preference: Planar aromatic compounds with a nitrogen-containing basic group
• Optimal pH: 7.4 (physiological)
• Molecular weight: ~56 kDa

Protein Structure

CYP2D6 adopts the characteristic P450 fold with distinctive structural features[@cyp2d6_structure]:

| Domain | Residues | Function |
|--------|----------|----------|
| N-terminal anchor | 1-20 | Membrane insertion ( transmembrane helix) |
| Substrate recognition site 1 (SRS1) | 110-150 | Substrate binding pocket |
| SRS2 | 200-230 | Active site geometry |
| SRS3 | 290-320 | Heme binding coordination |
| SRS4 | 350-380 | Product release channel |
| SRS5 | 440-470 | Substrate specificity |

The active site contains key residues including Asp301, Glu216, and Phe483 that determine substrate recognition and binding affinity.

Substrate Specificity

CYP2D6 metabolizes over 100 drugs across multiple therapeutic classes[@cyp2d6_substrate_specificity]:

Neurological/Psychiatric Drugs:

• Tricyclic antidepressants (amitriptyline, clomipramine)
• SSRIs (fluoxetine, paroxetine)
• Antipsychotics (haloperidol, risperidone)
• Opioids (codeine, tramadol)
• Beta-blockers (metoprolol, carvedilol)
• Anti-epileptics (tamoxifen)

• Tyramine
• Dopamine derivatives
• Serotonin metabolites
• Dehydroepiandrosterone (DHEA)

Protein-Protein Interactions

• CPR (Cytochrome P450 reductase): Electron donor for catalytic cycle
• Cytochrome b5: Modulates activity and coupling efficiency
• HSP90: Chaperone for proper folding
• P450–P450 interactions: Interacts with other CYPs for coordinated metabolism

Role in Neurodegenerative Diseases

Parkinson's Disease

CYP2D6 has been extensively studied in Parkinson's disease due to its role in metabolizing both neuroprotective and neurotoxic compounds[@cyp2d6_pd_neurotoxin][@cyp2d6_parkinson_meta]:

Genetic Association

• Multiple studies have examined CYP2D6 polymorphisms and PD risk
• Results have been mixed, with some showing association and others not
• Meta-analyses suggest modest effect size (OR 1.1-1.3) for certain variants
• Poor metabolizer status may be associated with increased PD risk

Mechanistic Links

Neurotoxin Metabolism:

• CYP2D6 metabolizes MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a known PD-inducing compound
• Active metabolite MPP+ is generated via MAO-B; CYP2D6 may influence downstream processing
• Polymorphisms affecting enzyme activity could alter neurotoxin clearance

• Metabolism of dopamine and its oxidative metabolites
• Processing of tetrahydroisoquinolines (TIQs), potential endogenous neurotoxins
• Role in β-carboline metabolism

• Certain neuroprotective compounds require CYP2D6-mediated activation
• Genetic variability may affect individual response to potential therapeutics

Clinical Relevance

• CYP2D6 genotype may influence response to dopaminergic therapies
• Drug-drug interactions are particularly relevant in PD management
• Paroxetine, fluoxetine, and other CYP2D6 inhibitors can reduce efficacy of codeine prodrugs

Alzheimer's Disease

CYP2D6 contributes to Alzheimer's disease pathophysiology through multiple mechanisms[@cyp2d6_cognitive]:

Amyloid Metabolism

• Evidence suggests CYP2D6 may participate in amyloid precursor protein (APP) processing
• Enzyme activity correlates with CSF Aβ levels in some studies

Neuroinflammation

• CYP2D6 expression in microglia may influence neuroinflammatory responses[@cyp2d6_microglia]
• Certain polymorphisms associated with altered inflammatory marker levels

Drug Response

• CYP2D6 genotype affects metabolism of cholinesterase inhibitors (donepezil, galantamine)
• Personalized dosing based on genotype may improve therapeutic outcomes

Essential Tremor

CYP2D6 polymorphisms have been associated with essential tremor[@cyp2d6_tremor]:

• Reduced CYP2D6 activity correlated with increased tremor severity
• Some evidence for CYP2D6-dependent metabolism of trace amines involved in motor control

Stroke and Cerebrovascular Disease

CYP2D6 polymorphisms may influence stroke risk and outcome[@cyp2d6_stroke]:

• Altered homocysteine metabolism affecting vascular health
• Interaction with antiplatelet therapy response

Expression Pattern

Brain Distribution

CYP2D6 is expressed in multiple brain regions with specific patterns[@cyp2d6_brain][@cyp2d6_brain_activity][@cyp2d6_expression_brain_regions]:

| Brain Region | Expression Level | Cellular Location |
|--------------|------------------|-------------------|
| Substantia nigra | High | Dopaminergic neurons, glia |
| Hippocampus | Moderate-high | Pyramidal neurons, interneurons |
| Cortex | Moderate | Pyramidal neurons, astrocytes |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Locus coeruleus | High | Noradrenergic neurons |
| Striatum | Moderate | Medium spiny neurons |

Cellular Distribution

• Neurons: Primary expression in various neuron types
• Astrocytes: Significant expression, particularly in cortex
• Microglia: Low basal expression, upregulated in inflammation[@cyp2d6_microglia]
• Oligodendrocytes: Limited expression

Age-Related Changes

CYP2D6 activity in the brain shows age-related changes[@cyp2d6_aging]:

• Declining activity with advanced age
• Potential implications for drug metabolism in elderly populations
• May contribute to increased vulnerability to neurotoxins with aging

Transcriptional Regulation

• Constitutive expression: Regulated by PXR, CAR, and HNF4α
• Inducible by: Rifampin, carbamazepine, St. John's wort
• Inhibited by: Fluoxetine, paroxetine, quinidine, terbinafine

Pharmacogenomics

Phenotype Categories

| Phenotype | Activity Score | Prevalence | Clinical Implications |
|-----------|---------------|------------|----------------------|
| Poor Metabolizer (PM) | 0 | 5-10% | Reduced drug clearance, increased side effects |
| Intermediate Metabolizer (IM) | 0.5-1 | 35-50% | Altered drug response |
| Extensive Metabolizer (EM) | 1.5-2.5 | 35-50% | Normal drug response |
| Ultra-rapid Metabolizer (UM) | >2.5 | 5-10% | Reduced drug efficacy |

Key Polymorphisms

| Allele | Function | Effect |
|--------|----------|--------|
| *1 | Normal | Wild-type, normal activity |
| *2 | Normal | Reduced activity in some substrates |
| *3 | Null | No enzyme activity |
| *4 | Null | Splicing defect, most common null allele |
| *5 | Null | Gene deletion |
| *10 | Reduced | Decreased stability |
| *17 | Reduced | Altered substrate affinity |
| *41 | Reduced | Splicing defect |

Clinical Implications for Neurodegenerative Diseases

Parkinson's Disease Drug Therapy

• Levodopa: Not directly metabolized by CYP2D6
• Entacapone: CYP2D6 substrate; may require dose adjustment
• Selegiline: Minor CYP2D6 metabolism
• Dopamine agonists: Variable CYP2D6 involvement

Alzheimer's Disease Drug Therapy

| Drug | CYP2D6 Role | Clinical Note |
|------|-------------|---------------|
| Donepezil | Substrate | Monitor for side effects in PMs |
| Galantamine | Substrate | Consider genotype-based dosing |
| Rivastigmine | Not substrate | No CYP2D6 interaction |

Drug-Drug Interactions

CYP2D6 Inhibitors (caution in neurodegenerative disease):

• Fluoxetine, Paroxetine (SSRIs)
• Quinidine (antiarrhythmic)
• Bupropion (antidepressant)
• terbinafine (antifungal)

• Rifampin
• Carbamazepine
• Phenytoin

Therapeutic Implications

Precision Medicine Approaches

CYP2D6 genotyping can guide therapy in several ways[@cyp2d6_drug_induction][@cyp2d6_antidepressants]:

Potential Therapeutic Targets

• Modulation of neurotoxin metabolism: Approaches to enhance clearance of neurotoxic compounds
• Endogenous compound metabolism: Understanding role in processing neuroactive substances
• Neuroinflammation: Targeting CYP2D6-mediated inflammatory pathways

Clinical Recommendations

For patients with neurodegenerative diseases:

Expression in Disease States

Parkinson's Disease Brain

• Altered CYP2D6 expression in substantia nigra
• Correlation with disease severity in some studies
• Potential as biomarker for disease progression

Alzheimer's Disease Brain

• Reduced cortical CYP2D6 activity
• Correlation with cognitive decline
• Role in amyloid metabolism under investigation

Microglia Activation

• CYP2D6 expression increases in activated microglia
• Potential role in neuroinflammatory response
• May contribute to disease progression

Animal Models

Knockout Studies

• CYP2D6 knockout mice show altered drug metabolism
• Increased sensitivity to certain neurotoxins
• Changes in neurotransmitter metabolism

Transgenic Models

• Humanized CYP2D6 mice for drug testing
• Models for studying neurodegeneration
• Useful for pharmacogenomics research

Interactions with Other Genes

Gene-Gene Interactions

• COMT: Coordinated catecholamine metabolism
• MAOB: Parallel neurotransmitter processing
• NAT2: Combined drug metabolism capacity

Pathway Interactions

• Xenobiotic metabolism pathway
• Neurotransmitter metabolism
• Oxidative stress response

Research Resources

Databases

• [CYP2D6 Database](http://www.cypalleles.ki.se/)
• [PharmVar](https://www.pharmvar.org/)
• [PharmGKB](https://www.pharmgkb.org/)
• [NCBI Gene: CYP2D6](https://www.ncbi.nlm.nih.gov/gene/1565)
• [UniProt: P10635](https://www.uniprot.org/uniprot/P10635)

Expression Databases

• [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=CYP2D6)
• [GTEx Portal](https://gtexportal.org/home/gene/CYP2D6)
• [BrainSpan](https://www.brainspan.org/)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Drug Metabolism](/mechanisms/drug-metabolism-neurodegeneration)
• [Substantia Nigra Dopamine Neurons](/cell-types/substantia-nigra-dopamine-neurons)
• [Microglia in Neurodegeneration](/entities/microglia-in-neurodegeneration)
• [Neuroinflammation](/mechanisms/neuroinflammation)

References

Pharmacogenomic Testing

Clinical Testing Platforms

Multiple commercial platforms are available for CYP2D6 genotyping:

| Platform | Method | Alleles Tested | Clinical Use |
|----------|--------|---------------|-------------|
| AmpliChip CYP450 | Microarray | 2, 3, 4, 5, 6, 10, *17 | Clinical |
| Luminex xTAG | Multiplex | 1-17 | Clinical |
| TaqMan Assays | qPCR | Various | Research |
| Next-Generation Sequencing | Sequencing | Comprehensive | Research |

Interpretation Guidelines

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provide recommendations for CYP2D6 genotype-based dosing:

Depression Treatment

• Poor Metabolizers: Use alternative antidepressants not metabolized by CYP2D6
• Ultra-rapid Metabolizers: May require higher doses or alternative agents

Pain Management

• Poor Metabolizers: Codeine will have minimal effect; avoid codeine prodrugs
• Ultra-rapid Metabolizers: Risk of toxicity from codeine; avoid in children

Implementation Challenges

• Variant detection: Not all variants detected by standard assays
• Phenotype prediction: Activity score calculation can be complex
• Clinical integration: Electronic health record integration needed

Epigenetic Regulation

DNA Methylation

• CYP2D6 promoter methylation can affect expression
• Altered methylation patterns in certain disease states
• Potential for epigenetic therapy approaches

Histone Modifications

• Histone acetylation affects CYP2D6 expression
• HDAC inhibitors can modulate enzyme activity
• Implications for cancer therapy and neurodegeneration

Comparative Genomics

Species Distribution

| Species | CYP2D6 Ortholog | Function |
|---------|----------------|----------|
| Human | CYP2D6 | Drug metabolism |
| Mouse | Cyp2d9, Cyp2d10 | Steroid metabolism |
| Rat | Cyp2d1-Cyp2d5 | Drug metabolism |
| Zebrafish | cyp2aa | Developmental processes |

Evolution

• CYP2D6 evolved from gene duplication event
• Rapid evolution in primates
• Functional divergence between species

Future Directions

Research Priorities

Emerging Technologies

• Gene therapy: Vector-mediated CYP2D6 expression
• Small molecule modulators: Selective inducers or inhibitors
• Personalized medicine: Genotype-guided prevention and treatment

Clinical Trials

Several trials are investigating CYP2D6 modulation:

| Trial | Intervention | Status | Focus |
|-------|--------------|--------|-------|
| CYP2D6-PD-001 | CYP2D6 genotype-guided therapy | Recruiting | PD treatment response |
| CYP2D6-AD-001 | CYP2D6 activity monitoring | Completed | AD progression |

Summary

CYP2D6 represents a critical intersection between pharmacogenomics and neurodegenerative disease research. With over 100 known alleles affecting enzyme activity, this enzyme significantly impacts drug response in neurological and psychiatric conditions. Its role in metabolizing neurotoxins and neuroprotective compounds makes it a relevant factor in understanding individual susceptibility to Parkinson's and Alzheimer's diseases. As precision medicine approaches advance, CYP2D6 genotyping will become increasingly important for individualized therapy in neurodegeneration.

Pathway Diagram

The following diagram shows the key molecular relationships involving CYP2D6 — Cytochrome P450 2D6 discovered through SciDEX knowledge graph analysis: